Raymond Blind, PhD, an American Cancer Society research grantee, and his research team developed a new type of technology that tests a patient’s prostate tumor to see how well it will respond to anti-cancer drugs.
Mingfeng Bai, PhD, American Cancer Society research grantee is trying to develop a light-sensitive compound that binds to cancer cells. The goal is for the compound to be especially attracted to ovarian cancer cells that are resistant to chemotherapy. Light will activate the compound to kill the cancer cells.